At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss due to a $15.2M non-cash charge tied to preferred stock valuation. The company has $7M in cash as of year-end 2025, with a proforma balance of $9M in January 2026, funding operations through Q4 2026. Clinical progress includes ongoing GTB-3650 enrollment and FDA clearance for GTB-5550, with a trial expected to start mid-2026.
- Cash and cash equivalents: $7M as of December 31, 2025; unaudited proforma cash of $9M as of January 31, 2026
- Net loss: $28.4M in 2025 vs. $13.2M in 2024, driven by a $15.2M non-cash expense from preferred stock valuation
- R&D expenses decreased to $3.5M from $5.8M due to lower production costs
- Loss from operations improved to $12.4M from $14.4M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access